Neovascular age-related macular degeneration
Conditions
Interventions
The second eyes were treated with the 12-month fixed-interval dosing of aflibercept (3-monthly loading injections followed by bimonthly injections)
Sponsors
Seoul National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who showed poor response to the 12-month as-needed dosing anti-VEGF treatment (3-monthly loadings followed by further injections as required) in their first eyes were prospectively recruited. Poor response was defined as follows: reduction of central macular thickness (CMT) < 25%, with persistence or new subretinal fluid (SRF) or intraretinal fluid (IRF), or change in best-corrected visual acuity (BCVA) < 5 letters.
Exclusion criteria
Exclusion criteria: 1) patients with neovascularized maculopathies other than AMD, 2) patients with a history of prior photocoagulation, intravitreal anti-VEGF injection, photodynamic therapy, intravitreal or sub-tenon steroid injection, vitrectomy surgery, or intravitreal gas injection, 3) patients with diabetic retinopathy or retinal vein occlusion, and 4) patients with coexisting epiretinal membranes or vitreomacular traction syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measures were the changes in BCVA, CMT, and retinal morphology, including the presence of SRF, IRF, and PED between the baseline and month 12. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome included the proportion that met the criteria of poor response after the 12-month treatment and the frequency distribution of the changes in retinal morphology. The outcome measures were evaluated in the first and second eye groups, respectively, and compared between the groups. | — |
Countries
Asia(except Japan)
Contacts
Public ContactDAE JOONG MA
Seoul National University Hospital Department of Ophthalmology
Outcome results
None listed